AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
News|Articles|May 4, 2022
Validair Launches New Company in Ireland
Author(s)Pharmaceutical Technology Editors
The new company has been appointed as a channel partner for Ireland by TSI Inc., a particle counter manufacturer.
Advertisement
Validair announced on May 1, 2022 that it has formed a new company that has been appointed as a channel partner for Ireland by TSI Inc., a particle counter manufacturer and contamination control company. The agreement will allow Validair Monitoring Ireland Limited to deliver services across Ireland from its headquarters in Dublin. The new company will offer the entire TSI range of products and access to more than 20 field service and specialist technical engineers in the pharmaceutical, life sciences, biotech and research, and healthcare markets.
“Validair companies have demonstrated impressive capabilities with more than 120 TSI systems installed in the [United Kingdom] over the past 20 years, including the largest-ever global installation at Oxford Biomedica. We are very confident that the new venture will deliver the same excellent level of results that Validair customers in other territories have come to expect,” said Simon Tebb, sales manager EMEA Controlled Environments at TSI Inc., in a press release.
Source:
Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
2
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
5